The company and one of its subsidiaries would allegedly confuse clinicians and have them bill government programs for cardiac monitoring services that were more expensive than what they needed. This settlement resolves those allegations. 

The Lower Costs, More Transparency Act requires radiologists to publicly list prices for certain "shoppable" services.

The company's Verafeye platform was designed to provide imaging guidance during cardiac procedures using advanced catheter sensors and deep learning. 

The doctor allegedly targeted some patients more than ten times, treating them again and again with procedures that were not medically necessary. 

Prosecutors successfully argued that the patient would not have died if clinicians had ordered a routine CT exam. 

The health system allegedly ended an ongoing contract with little notice, leaving clinicians and patients without the services of a cardiovascular surgery program. 

The funds are expected to go toward bringing in new employees and accelerating the development of a new cardiac imaging offering. 

According to Ajax Health CEO and industry veteran Duke Rohlen, the new company will be focused on offerings that "prioritize precision, simplicity and efficiency."